Niranjan Kanesa-Thasan, MD

Icosavax, AstraZeneca

Disclosure(s): Icosavax/AstraZeneca: Previous employee of Icosavax, a member of the AstraZeneca Group

Poster(s):

• (P-601) Safety and Immunogenicity of a Respiratory Syncytial Virus and Human Metapneumovirus Virus-like Particle Protein Subunit Combination Vaccine in 60–85-Year-Old Adults: Interim Results from a Phase 2a Clinical Trial
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT